Adolescents and young adults have been increasingly seeking care at gender clinics to discuss gender incongruence or dysphoria.1,2 Approximately 0.6% of adults in the United States are transgender.3 Younger people more frequently identify as transgender, with 1.8% of American high school students identifying as such in 2017.4 Up to 2.7% of high school students identified as transgender and/or gender non-conforming in certain states.5
Feelings of gender dysphoria may begin developing as early as the age of 7 years.6 Improved understanding and social destigmatization of gender incongruence have contributed to more transgender patients seeking gender-affirming care.7 Gender-affirming care for adolescents may involve psychosocial care, pubertal suppression, hormone therapy, and/or surgeries.8 This study aims to review: 1) the impact of gender-affirming care on skin and skin conditions in transgender adolescents; 2) management strategies of common dermatological conditions associated with gender-affirming care, and 3) creating a welcoming care environment for transgender adolescents to engage in dermatologic care. For this review, adolescence refers to the period between onset of puberty and 18 to match language in reviewed publications. Young adult refers to those between the ages of 18 and 25.9 Use of “youth” refers to both adolescents and young adults.
Terminology and Definitions
Terms related to transgender health evolve over time and may not be accepted by all members of transgender communities.10,11 We specified the definitions of common terms and concepts related to transgender health in Table 1. In this review, we will use the term transgender as an umbrella term for persons whose gender identity is incongruent with one’s assigned sex at birth.12 We will also use the terms describing health of transmasculine, transfeminine, or non-binary populations based on terms used in primary references. Usage of terms differs based on individual preference, as they describe personal gender experiences.11 Providers should use language and terminology that their patients prefer.13
Table 1 Definitions of Common Terms Related to Transgender Health
Overview of Gender-Affirming Care and Implications for Skin Conditions
Pubertal suppression via gonadotropin-releasing hormone (GnRH) agonists delays development of secondary sex characteristics. GnRH agonists inhibit pubertal androgen production, thus reducing androgen-mediated skin issues.18,19
Hormone therapy usually involves using testosterone for transmasculine patients and estrogen for transfeminine patients to develop secondary sex characteristics congruent with their gender identity. Testosterone therapy can cause acne and androgenic alopecia, while estrogen therapy could reduce acne but does not sufficiently reduce unwanted hair.13,20–22
Components of gender-affirming care, their dermatological effects, and corresponding management strategies are summarized in Table 2.
Table 2 Gender-Affirming Effect and Dermatological Impact of Pubertal Suppression
Acne Epidemiology and Impact of Pubertal Suppression on Acne
Acne affects approximately 85% of patients between the ages of 12–25.33 Acne is the third highest cause of disability-adjusted life year loss among skin diseases and the most common condition seen between the ages of 15–24 in outpatient dermatology practices.34,35 Acne typically starts in puberty due to hormonal changes.36 Severity of acne increases with Tanner stage.37,38 Gender dysphoria also increases around ages 10–13 as endogenous puberty begins and transgender adolescents undergo undesired Tanner development stages.39 Timing of pubertal acne and increasing levels of gender dysphoria thus overlap in transgender adolescents.
Reversible pubertal suppression via gonadotropin-releasing hormone (GnRH) agonists reduces dysphoria in transgender adolescents. Pubertal suppression, typically used from initiation of puberty up until age 16, delays the development of secondary sex characteristics and reduces associated gender dysphoria.11,40,41 Pubertal suppression provides time to explore gender identity before making informed decisions on gender-affirming hormone therapy.39,42–45 Multiple guidelines recommend pubertal suppression to reduce gender dysphoria for transgender adolescents starting puberty above Tanner stage 2 in the absence of contraindications.42,46,47 Pubertal suppression in transgender adolescents significantly improves general functioning and decreases depressive symptoms and suicidal ideation.48–50
Pubertal suppression could alleviate acne, reducing gender dysphoria and acne mental health burdens.51 In adults, GnRH agonists have been used to treat acne and hirsutism by suppressing androgen production.52,53 Pubertal suppression can temporarily exacerbate acne by simulating luteinizing hormone and follicle-stimulating hormone.39 This transient effect generally resolves with continued pubertal suppression.39
Patients receiving pubertal suppression and estrogen/testosterone therapy concurrently required lower doses of hormones to reach gender expression goals compared to patients receiving estrogen/testosterone therapy alone.54 The impact of pubertal suppression on acne incidence and severity, as well as other long-term skin health outcomes, remains to be explored.55 Increased research would help inform healthcare providers on the effects of pubertal suppression.
Impact of Gender-Affirming Hormone Therapy on Acne
For transmasculine adolescents, testosterone therapy can generate or worsen acne.13 In transmasculine individuals taking testosterone, acne commonly develops over the lower third of the face, chest, upper arms, and back – similar in location to hormonal acne in cisgender individuals.13,56
Few studies explored acne epidemiology in transgender adolescents. For transmasculine adolescents using Lynestrenol (a progestin) to induce amenorrhea, acne significantly increased after starting testosterone in combination with Lynestrenol.57 Acne became most prevalent between 6 and 12 months of testosterone therapy for adolescents starting testosterone therapy after pubertal suppression.58 29.6% of young transmasculine adults aged 18–21 experienced acne over 2 years of testosterone treatment, in a study of 988 transmasculine patients.59 Younger age at time of testosterone initiation increases acne incidence, and participants between the ages of 18–25 had the greatest acne risk.59 Transgender young men between 18–29 experience the most moderate-to-severe acne compared to older transgender men.60 Severity of acne presentation has not been systemically studied in transgender adolescents.
Little data exists on dermatologic effects of hormone therapy for transfeminine patients. Estrogen therapy and spironolactone, an anti-androgen, reduce sebum and decrease acne in transfeminine adults.21,61,62
GnRH agonists into adulthood or selective estrogen receptor modulators (SERMs) have been reported for use in gender-affirming therapy for non-binary individuals.63,64 SERMs contribute to skin elasticity in softness in post-menopausal cisgender women, but dermatologic effects have not been explored for non-binary patients.63
Mental Health Among Acne Patients and in Transgender Adolescents
Studies have thoroughly documented acne’s association with mental health comorbidities in the general population. Acne increases depression and anxiety among adolescents.65 Adolescent females tend to have worse mental health burden than adolescent males.66–68
Increasing acne severity in adolescents correlates increased social impairment, lower attachment to friends, and less experience with romantic relationships.69 Increasing perceived social stigma due to acne predicts quality of life impairment among adolescents and young adults.70 Adolescents and young adults with acne have increased association with suicide (either ideation, attempt, or death).71 Concerns about perceived adverse effects, effectiveness of acne treatments, and perceived medical provider trivialization exacerbate psychological impact.72
Few studies linking acne with adverse mental health outcomes focus on transgender and gender non-conforming adolescents, despite their disproportionate mental health burden.73,74 Transgender adolescents experience more bullying in school and have a severalfold higher suicide risk than cisgender adolescents.4,75,76 10% reported leaving school due to mistreatment and lack of support from teachers and peers.77 Transgender and non-binary youth experience increased risk of negative mental health outcomes in comparison to cisgender sexual minority adolescents.78 Socially transitioned transgender pre-pubescent children between 3–12 years have depression and anxiety levels comparable to their cisgender siblings and age-matched peers, suggesting social support throughout transition may reduce negative mental health outcomes.79 Family-connectedness, teacher support, and feeling safe in one’s community protect against negative mental health outcomes among transgender adolescents.5,80 Receiving gender-affirming hormone therapy decreases depression and suicidality and improves well-being.49,81,82
Transmasculine adults receiving testosterone with current moderate-to-severe acne (defined by the patient) reported increased anxiety and depression symptoms compared to those who never had acne in a survey of 283 patients.83 Further research could help characterize how acne’s mental health burden affects not only adults but adolescent transgender patients as well.
Medical provider practices promoting inclusivity improve transgender patient mental health outcomes. Transgender adolescents tend to seek dermatological care from doctors who identify as a sexual or gender minority because of the expectation they will be more respectful toward and more knowledgeable about transgender patient skin conditions.84 More research could characterize how provider-patient relationships affect mental health among transgender adolescents, as most existing literature focuses on transgender adults’ relationships with medical providers. 25.4% of transgender adults postponed medical care when sick because of anticipated discrimination from healthcare providers, and 19% were at some point refused medical treatment due to their gender identity.77,85 Transgender adults reported better mental health if they felt respected by their physician.86 Transgender adults’ perceived healthcare provider comfort with their gender identity predicts wellbeing, independent of health status.87
Current Management Strategies for Acne: Considerations for a Gender Diverse Population
Healthcare providers should proactively address acne as a side effect of gender-affirming care. Successful management of acne results in noticeable improvements when comparing before (Figure 1A and B) and after (Figure 1C and D) treatment.
Figure 1 (A and B) Images of patient before acne treatment (C and D) Improved acne after 3 months of oral doxycycline, benzoyl peroxide wash, and topical tretinoin followed by 2 months of isotretinoin.
Before initiating acne treatment, providers should conduct an organ inventory to assess childbearing potential as many acne treatments are teratogenic.13 In patients who can become pregnant and need teratogenic medication, contraceptive needs and sexual behaviors should not be assumed but rather thoughtfully explored. While conducting organ inventory, providers should use general terms such as “chest” and “genitalia” instead of “breast”, “vagina”, or “penis” to avoid triggering gender dysphoria.88 Pregnancy can occur in transmasculine patients with retained functional uterus and ovaries during and after testosterone therapy if they engage in penis-vagina sexual intercourse with sperm-producing partners.89 Contraception is important for transmasculine persons who can become pregnant who require teratogenic acne mediations, as discussed in detail in the following isotretinoin section.90 Transmasculine patients who have undergone hysterectomy and/or bilateral oophorectomy would not need contraception while taking teratogenic medications.88
With no current evidence-based guidelines for treating hormonal acne in testosterone therapy, treatment plans use guidelines established for treating acne in cisgender persons not receiving hormone therapy.51 Acne is classified as mild, moderate, or severe. Mild acne encompasses having some comedones and no more than a few papules/pustules, moderate acne has some papules/pustules and no more than one nodule, and severe acne consists of having more than one nodule.26
Topical retinoids like adapalene and tretinoin treat mild to moderate comedonal and inflammatory acne. Topical trifarotene has been specifically studied for treating truncal acne,25 which may be more prominent in patients with testosterone-induced acne. Topical retinoids carry a teratogenic risk and providers should advise patients appropriately.
Topical antibiotics like clindamycin and erythromycin manage mild to moderate acne. Topical antibiotics are often combined with topical benzoyl peroxide to mitigate the risk of resistance and improve effectiveness.26
Topical antiandrogens, such as clascoterone, treat both inflammatory and non-inflammatory facial acne with minimal adverse effects or safety concerns.91 Although clascoterone clinical trials did not document gender-affirming hormone therapy use in participants, topical antiandrogens in transmasculine patients could reduce testosterone action in the skin and curb acne development.27
Oral antibiotics, such as doxycycline and minocycline, treat moderate-to-severe acne or acne affecting a large body surface area.28 As doxycycline carries possible teratogenic risk, providers should notify and counsel patients with childbearing potential.92
Spironolactone effectively treats acne in cisgender women.93 Transfeminine patients report improvement in their acne with spironolactone treatment in addition to other anti-androgenic effects which facilitate their transition goals.21 In transmasculine patients, although spironolactone may hypothetically improve acne, it may contradict transition goals by causing irregular bleeding and gynecomastia.94 As an anti-androgen, spironolactone is counterproductive to testosterone therapy.95 Spironolactone carries a teratogenic potential that should be addressed in patients with childbearing potential.96
Hormonal contraceptives address contraception as part of acne treatment but are generally not used as a primary treatment for acne in transmasculine patients.13 Combined oral contraceptives (COCs) containing ethinyl estradiol both treat acne and provide contraception in cisgender women.97 For transmasculine patients, COCs have feminizing effects which may contradict transition goals.98 Progestin-only contraceptives, such as norethinsterone (also known as norethindrone), cease uterine bleeding in alignment with transition goals for transmasculine patients. However, progestin-only contraceptives (including long-acting reversible contraception) could exacerbate acne.13
Oral isotretinoin is indicated for managing scarring acne, moderate acne refractory to other treatments, severe acne, and acne causing psychosocial distress.26 As isotretinoin’s severe teratogenic effects may lead to fetal death, the US Food and Drug Administration requires all patients taking it to be registered in the iPLEDGE program. Effective December 13th, 2021, iPLEDGE program categorizes patients into “patients who can become pregnant” and “patients who cannot get pregnant.”99 While the new gender-neutral classification may not be completely inclusive, it moves towards more inclusive care. iPLEDGE requires patients who can get pregnant to receive monthly contraceptive counseling and pregnancy testing in addition to committing to either complete abstinence with sperm-producing partners or consistent use of two forms of contraception.100 Testosterone therapy, even if amenorrhea is achieved, is neither a reliable contraception method nor a contraindication to other forms of contraception.90,101 In patients who qualify for isotretinoin treatment and are under the age of 18 years, a parent or a legal guardian should read, understand, and sign iPLEDGE.100 However, adolescent patients should be reassured that their confidentiality will be preserved except in cases of abuse that legally require disclosure.
Dermatologic Impacts of Chest Binding, Tucking, and Packing
Although not gender-affirming measures usually provided by clinicians, healthcare providers should familiarize themselves with chest binding, tucking, and packing and associated dermatologic impacts.
Many young transmasculine patients use chest binding to flatten the chest and relieve gender dysphoria before they can get gender-affirming chest reconstruction surgery.102–104 They commonly use commercial binders designed for tight compression, although some use other methods (including elastic bandages or tape) based on financial means and/or parental support.105 Chest binding prevents misgendering and promotes safety and confidence.104 Binding, especially with high frequency, can cause physical side effects.105,106 Chest size correlates with dermatological problems when binding.105 Acne, itch, skin infection, and skin changes affect most who bind.102 33.3% and 45.1% of youth who bind experience acne and itch respectively within the first year of binding, in a survey of 1800 individuals.103 Skin changes, such as skin infection and reduced elasticity, have lower prevalence and a later onset.103 Decreased skin elasticity from chest binding limits options for and/or negatively influences the outcome of gender-affirming chest reconstruction surgery.31,107–109 For patients with decreased skin elasticity, more extensive chest incisions may be required for gender-affirming chest surgery to avoid wrinkling and unevenness of excess skin, resulting in more scarring.110 Prevention of unwanted chest development through pubertal suppression decreases need for chest binding.103
Providers can manage symptoms associated with binding while recognizing the importance of binding for safety and mental health. Aside from addressing acne, providers can help reduce itch with topical emollients.111 Skin infections diagnosed early and treated with appropriate antibiotics have good outcome.112 Although 82.3% of transgender patients recognize the importance of discussing binding with healthcare providers, 56.3% feel safe and comfortable initiating conversation about binding.102 Insensitivity and lack of understanding from healthcare professionals present a large obstacle to care.113 Currently, almost all trans youth report learn about binding online, not in healthcare settings.105 Reduced time binding lessens physical symptoms, but the balance between side effects and benefits of binding depends on the informed decision of the patient.103,106 Health providers can help patients determine their binder sizing and improve accessibility for commercial binders, especially if patients have parental or financial obstacles.104 These measures could help reduce long-term skin and tissue changes.
Similar to binding, tucking or packing help relieve dysphoria non-surgically.114 Tucking in transfeminine individuals involves placing testes upwards, close to the inguinal canal, and securing external genitalia between the legs to flatten the lower pelvis.114,115 70% of transfeminine patients report tucking, with 28%, 21%, and 12% experiencing itch, rash, and skin infection respectively.115 In a survey of 79 transfeminine adults, itching, rash, and testicular pain were the most commonly reported health effects.116 For itch and rash in the groin area, topical emollients to repair skin barrier and antihistamines to suppress the itch-scratch-itch cycle can help.117 Skin infection should be diagnosed and treated promptly with the appropriate antibiotics.112 Transmasculine patients may also “pack” or use “packers” in the underwear to give the appearance of a bulge.114,118 This may cause irritation of tissue in the area.118 Further research is needed to inform clinicians on how to address dermatologic effects of tucking or packing.
Hair Therapy: Impacts of Gender-Affirming Hormone Therapy and Dermatological Strategies to Reduce Gender Dysphoria
Hair growth and/or removal can be an essential element of gender-affirming therapy.119 There is limited data on hair growth for transmasculine adolescents on testosterone. Preliminary data suggests topical minoxidil can help growth of pigmented hair in desired patterns in transmasculine adolescents, including those with limited access to testosterone therapy.120 In transmasculine adults, testosterone therapy significantly increases facial, chest, and abdominal hair growth.121,122 Androgenic alopecia from testosterone therapy, seen in some young adults, may be treated by 5-alpha-reductase inhibitors like finasteride.29 However, 5-alpha-reductase inhibitors may reduce systemic testosterone effects.20,123
84% of transgender women receiving estrogen still report persistent excess facial and body hair.22 This may affect transfeminine adolescents, depending on the stage of puberty. Treatment with cyproterone acetate (note: not available in the USA), an anti-androgen, either alone or in combination with estrogens, reduces the need for facial shaving in transfeminine patients in late adolescence.30
As hormone therapy and pubertal suppression affect hair distribution, temporary solutions like wigs, hair extensions, and hair drawing could facilitate desired gender expression until hormonal effects on hair stabilize. After hair distribution stabilizes, patients can consider more permanent solutions such as hair transplant and hairline lowering surgery.124
For patients who desire hair removal, solutions like shaving, waxing, and depilatory creams may not achieve the desired transition effect. Transfeminine patients can use laser hair removal to safely and effectively reduce unwanted hair.125 Laser hair removal uses light to target hair melanin to destroy follicular bulbs and usually takes up to 6 sessions, each spaced 6 weeks apart.125–127 Laser hair removal is less effective in patients with fairer hair and/or darker skin.128
Transfeminine patients can also reduce unwanted hair via electrolysis. In electrolysis, probes use electrical current to destroy hair follicles.128 Electrolysis can remove any hair color and performs well with fairer hair, unlike laser hair removal.129 Electrolysis often spans over a year or more, with sessions every one or two weeks. Patients report more pain with electrolysis compared to laser hair removal.129,130 Transfeminine patients note inability and/or unwillingness to grow out facial hair for electrolysis.128
Patients who have undergone hair treatment as part of their transition have reported less distress, better subjective well-being, and more body satisfaction compared to their peers.128,131 Transition hair goals should be explored and not assumed based on cisnormative standards. Providers should explore the patients’ hair pattern prior to and during transitioning, family history of hair loss and hirsutism, and possible underlying endocrine and skin conditions that may affect the hair. Patients can be asked to bring model photos and/or draw lines of desired hair distribution.
Dermatological Considerations for Gender-Affirming Surgery
Transmasculine adolescents can undergo gender-affirming chest reconstruction surgery, also known as “top surgery.”31 Top surgery improved quality of life, functioning, and mental health, as testosterone therapy alone was inadequate in relieving gender dysphoria.17,132 Patients may choose “keyhole” or “periareolar” surgery, associated with less scarring.31,133 Patients with reduced skin elasticity or more chest tissue often undergo the “double incision free nipple graft” procedure instead, associated with increased scarring but better outcomes.31,133,134
Isotretinoin may lead to delayed wound healing persisting up to one year after discontinuation, posing a challenge gender-affirming surgery recovery.26 Transgender patients with recent or upcoming surgeries with truncal acne could use oral antibiotics instead to reduce inflammation and scarring and optimize surgical outcomes.13
After gender-affirming surgery, providers should review scar aftercare with patients. Silicone gel improves outcome of surgical wounds.135 Ablative laser resurfacing can remodel scars, and non-ablative lasers help reduce redness of scars.136 Surgical revision techniques, such as a Z-plasty, improve scar aesthetics.137 Transgender patients also get tattoos to cover scars.138 Specialized medical tattooing, known as dermatography, smoothens scars and improves aesthetics.139 Treatment of top surgery scars with a novel topical spironolactone gel resulted in significantly higher patient satisfaction compared with silicone gel alone. Because testosterone could exacerbate scar tissue and keloid development, topical spironolactone could reduce scarring while avoiding undesired anti-androgenic systemic effects of oral spironolactone.32
Hypertrophic scars and keloids can develop because of surgery.31,40,140 Care for keloids generally consists of intralesional corticosteroid injections.141 Other treatments for keloids include silicone gel/sheets, cryotherapy, radiation, and laser therapy.23,24,142 Data regarding keloid treatment comes from general population studies, so further research on how keloid treatments may interact with gender-affirming therapy could help inform care.
Scar revision and treatment for hypertrophic scars applies to other gender-affirming surgeries. For instance, some transmasculine young adults undergo hysterectomy.143 Scarring can be reduced through minimally invasive hysterectomies.144,145 Other gender-affirming surgeries, which most patients undergo at an older age, include vaginoplasty, metoidioplasty, phalloplasty, and breast augmentation surgery.146–150
Improving General Care for Transgender Adolescents: Creating a Welcoming Clinical Setting
Creating a welcoming clinical environment is key to providing a positive healthcare experience for transgender adolescents.13 Some transgender patients avoid seeking healthcare due to anticipated discrimination, cisnormativity, or harassment within healthcare settings.151 Transgender knowledge incompetency of providers and staff, inadequate insurance, and socioeconomic barriers prevent ideal healthcare for transgender patients.152
A successful medical encounter with a transgender patient starts with fostering a gender-inclusive environment including gender-neutral intake forms with no identity assumptions, available all-gender restrooms, and welcoming signs that show support and alliance to transgender patients.101,153 Familiarity with common terminology used by transgender patients facilitates patient-provider conversations.13 Patient-centered language adaptation includes but is not limited to the names and pronouns the patients use in addition to their terms for sexual orientation, gender identity, sexual behavior, and anatomy.11 As some transgender people use names different from the names listed in the medical or legal records, patients should be routinely asked how they should be addressed.13 As sexual orientation and gender identity are fluid, providers should routinely explore and document them on medical records.13 Patients have positively responded to routine collection of sexual orientation and gender identity, which has been advocated for in dermatologic care.154
Providers introducing themselves with their pronouns or wearing pronoun pins may further promote a gender-inclusive environment.13 Physical examination should focus on relevant body parts to the chief complaint with obtaining constant consent prior to examining each body part and bearing in mind that some patients may wear chest binders or other gender-affirming devices.13 To further strengthen rapport, patients should be empowered to take the lead in showing the body parts that are both relevant to the encounter and the patient is comfortable with showing.155
Acne treatments may interfere with transition goals, as anti-androgenic compounds and some hormonal contraceptives contradict gender expression goals for transmasculine patients while isotretinoin interferes with wound healing for gender-affirming surgeries. Acne treatment prescribers should also consider logistics behind prescribing acne medications (ie iPLEDGE) or teratogenic risks for patients. Providers should hold a thorough and gender-affirming discussion with transgender patients to better set expectations and learn about transition goals.
Isotretinoin has been associated with psychiatric disturbances such as depression, anxiety, and suicidality.156 Conversely, other studies report that isotretinoin improves depressive symptoms and quality of life in patients with moderate and severe acne.157 Of note, transgender persons have a higher prevalence of depression, anxiety, and suicidality compared to their cisgender peers.158 Providers should routinely screen and monitor for signs of depression and mental health comorbidities in transgender patients, especially those receiving isotretinoin.
Optimal care for transgender patients fosters their transition goals and physical/mental well-being. To achieve this, healthcare providers should ensure multidisciplinary care with clear communication between the patients’ dermatologist, primary care provider, hormone provider, gender-affirming surgeon, reproductive health specialist, and mental health provider.13
To provide comprehensive care to transgender adolescents, providers should understand the dermatological impact of gender-affirming therapy. Increased research on transgender healthcare would clarify skin impacts of gender-affirming therapy. Further research is needed to characterize the impact of GnRH agonists on skin in transgender adolescents. Research should explore whether testosterone-induced acne can be prevented or mitigated. Information about how estrogen therapy affects acne and acne medication considerations for transfeminine patients is lacking. Studies investigating whether acne treatment improves mental health outcomes in transgender teenagers receiving hormone therapy can help providers address side effects with the most impact. Studies should monitor how emerging gender-affirming therapies affect the skin and establish care guidelines that address skin effects while achieving gender affirmation goals.
The patient in Figure 1 has provided informed consent for the publication of images.
Dr Yeung is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases under award numbers L30AR076081 and K23AR075888. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or US Department of Veterans Affairs. The authors report no other conflicts of interest in this work.
1. Bonifacio HJ, Rosenthal SM. Gender Variance and Dysphoria in Children and Adolescents. Pediatr Clin North Am. 2015;62(4):1001–1016. doi:10.1016/j.pcl.2015.04.013
2. Chen M, Fuqua J, Eugster EA. Characteristics of Referrals for Gender Dysphoria Over a 13-Year Period. J Adolesc Health. 2016;58(3):369–371. doi:10.1016/j.jadohealth.2015.11.010
3. Flores AR, Herman JL, Gates GJ, Brown TN How Many Adults Identify as Transgender in the United States?; 2016. Available from: https://williamsinstitute.law.ucla.edu/publications/trans-adults-united-states/.
4. Johns MM, Lowry R, Andrzejewski J, et al. Transgender Identity and Experiences of Violence Victimization, Substance Use, Suicide Risk, and Sexual Risk Behaviors Among High School Students – 19 States and Large Urban School Districts, 2017. MMWR Morb Mortal Wkly Rep. 2019;68(3):67–71. doi:10.15585/mmwr.mm6803a3
5. Eisenberg ME, Gower AL, McMorris BJ, Rider GN, Shea G, Coleman E. Risk and Protective Factors in the Lives of Transgender/Gender Nonconforming Adolescents. J Adolesc Health. 2017;61(4):521–526. doi:10.1016/j.jadohealth.2017.04.014
6. Zaliznyak M, Bresee C, Garcia MM. Age at First Experience of Gender Dysphoria Among Transgender Adults Seeking Gender-Affirming Surgery. JAMA Netw Open. 2020;3(3):e201236. doi:10.1001/jamanetworkopen.2020.1236
7. Skordis N, Kyriakou A, Dror S, Mushailov A, Nicolaides NC. Gender dysphoria in children and adolescents: an overview. Hormones. 2020;19(3):267–276. doi:10.1007/s42000-020-00174-1
8. Mahfouda S, Moore JK, Siafarikas A, et al. Gender-affirming hormones and surgery in transgender children and adolescents. Lancet Diabetes Endocrinol. 2019;7(6):484–498. doi:10.1016/S2213-8587(18)30305-X
9. Scales PC, Benson PL, Oesterle S, Hill KG, Hawkins JD, Pashak TJ. The dimensions of successful young adult development: a conceptual and measurement framework. Appl Dev Sci. 2016;20(3):150–174. doi:10.1080/10888691.2015.1082429
10. Turban JL, Ehrensaft D. Research Review: gender identity in youth: treatment paradigms and controversies. J Child Psychol Psychiatry. 2018;59(12):1228–1243. doi:10.1111/jcpp.12833
11. Rafferty J, Yogman M, Baum R. Ensuring Comprehensive Care and Support for Transgender and Gender-Diverse Children and Adolescents. Pediatrics. 2018;142(4). doi:10.1542/peds.2018-2162
12. Gamarel KE, Reisner SL, Laurenceau J-P, Nemoto T, Operario D. Gender minority stress, mental health, and relationship quality: a dyadic investigation of transgender women and their cisgender male partners. J Family Psychol. 2014;28(4):437. doi:10.1037/a0037171
13. Radi R, Gold S, Acosta JP, Barron J, Yeung H. Treating Acne in Transgender Persons Receiving Testosterone: a Practical Guide. Am J Clin Dermatol. 2022;23(2):219–229. doi:10.1007/s40257-021-00665-w
14. Guss C, Shumer D, Katz-Wise SL. Transgender and gender nonconforming adolescent care: psychosocial and medical considerations. Curr Opin Pediatr. 2015;27(4):421–426. doi:10.1097/MOP.0000000000000240
15. Matsuno E, Budge SL. Non-binary/genderqueer identities: a critical review of the literature. Current Sexual Health Rep. 2017;9(3):116–120. doi:10.1007/s11930-017-0111-8
16. Goldhammer H, Malina S, Keuroghlian AS. Communicating With Patients Who Have Nonbinary Gender Identities. Ann Fam Med. 2018;16(6):559–562. doi:10.1370/afm.2321
17. Olson-Kennedy J, Warus J, Okonta V, Belzer M, Clark LF. Chest Reconstruction and Chest Dysphoria in Transmasculine Minors and Young Adults: comparisons of Nonsurgical and Postsurgical Cohorts. JAMA Pediatr. 2018;172(5):431–436. doi:10.1001/jamapediatrics.2017.5440
18. Robeva R, Assyov Y, Tomova A, Kumanov P. Acne vulgaris is associated with intensive pubertal development and altitude of residence–A cross-sectional population-based study on 6200 boys. Eur J Pediatr. 2013;172(4):465–471. doi:10.1007/s00431-012-1907-1
19. Napolitano M, Ruggiero G, Monfrecola G, Megna M. Acne prevalence in 9 to 14-year-old old patients attending pediatric ambulatory clinics in Italy. Int J Dermatol. 2018;57(11):1320–1323. doi:10.1111/ijd.14138
20. Marks DH, Senna MM. Androgenetic Alopecia in Gender Minority Patients. Dermatol Clin. 2020;38(2):239–247. doi:10.1016/j.det.2019.10.010
21. Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab. 2000;85(8):2913–2921. doi:10.1210/jcem.85.8.6710
22. Marks DH, Hagigeorges D, Manatis-Lornell AJ, Dommasch E, Senna MM. Excess hair, hair removal methods, and barriers to care in gender minority patients: a survey study. J Cosmet Dermatol. 2020;19(6):1494–1498. doi:10.1111/jocd.13164
23. Betarbet U, Blalock TW. Keloids: a Review of Etiology, Prevention, and Treatment. J Clin Aesthet Dermatol. 2020;13(2):33–43.
24. Commander SJ, Chamata E, Cox J, Dickey RM, Lee EI. Update on Postsurgical Scar Management. Semin Plast Surg. 2016;30(3):122–128. doi:10.1055/s-0036-1584824
25. Tan J, Thiboutot D, Popp G, et al. Randomized Phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–1699. doi:10.1016/j.jaad.2019.02.044
26. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973.e933. doi:10.1016/j.jaad.2015.12.037
27. Marks DH, Mansh MD. Potential Role for Topical Antiandrogens in the Management of Acne Among Patients Receiving Masculinizing Hormone Therapy. JAMA Dermatol. 2020;156(12):1380–1381. doi:10.1001/jamadermatol.2020.4380
28. Webster GF, Graber EM. Antibiotic treatment for acne vulgaris. Semin Cutan Med Surg. 2008;27(3):183–187. doi:10.1016/j.sder.2008.07.001
29. Motosko CC, Tosti A. Dermatologic Care of Hair in Transgender Patients: a Systematic Review of Literature. Dermatol Ther (Heidelb). 2021;11(5):1457–1468. doi:10.1007/s13555-021-00574-0
30. Tack LJW, Heyse R, Craen M, et al. Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents. J Sex Med. 2017;14(5):747–757. doi:10.1016/j.jsxm.2017.03.251
31. McEvenue G, Xu FZ, Cai R, McLean H. Female-to-Male Gender Affirming Top Surgery: a Single Surgeon’s 15-Year Retrospective Review and Treatment Algorithm. Aesthetic Surgery J. 2018;38(1):49–57. doi:10.1093/asj/sjx116
32. Tanini S, Calabrese S, Fisher AD, Maggi M, Lo Russo G. When Testosterone Needs to be Contrasted: a Preliminary Study of Scar Prevention in Transmen Top Surgery with an Innovative Galenic Preparation. Aesthetic Plast Surg. 2020;44(3):1006–1013. doi:10.1007/s00266-020-01678-2
33. Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolesc Health Med Ther. 2016;7:13–25. doi:10.2147/AHMT.S55832
34. Ho T, Taylor MT, Marathe KS, Lucky AW, Barbieri JS. Most common pediatric skin conditions managed in outpatient dermatology clinics in the United States stratified by race and ethnicity. Pediatr Dermatol. 2021;38(Suppl 2):129–131. doi:10.1111/pde.14693
35. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527–1534. doi:10.1038/jid.2013.446
36. Friedlander SF, Eichenfield LF, Fowler JF, Fried RG, Levy ML, Webster GF. Acne epidemiology and pathophysiology. Semin Cutan Med Surg. 2010;29(2 Suppl 1):2–4. doi:10.1016/j.sder.2010.04.002
37. Mancini AJ, Baldwin HE, Eichenfield LF, Friedlander SF, Yan AC. Acne life cycle: the spectrum of pediatric disease. Semin Cutan Med Surg. 2011;30(3 Suppl):S2–5. doi:10.1016/j.sder.2011.07.003
38. Lucky AW, Biro FM, Huster GA, Morrison JA, Elder N. Acne vulgaris in early adolescent boys. Correlations with pubertal maturation and age. Arch Dermatol. 1991;127(2):210–216. doi:10.1001/archderm.1991.01680020078009
39. Panagiotakopoulos L. Transgender medicine – puberty suppression. Rev Endocr Metab Disord. 2018;19(3):221–225. doi:10.1007/s11154-018-9457-0
40. Kosche C, Mansh M, Luskus M, et al. Dermatologic care of sexual and gender minority/LGBTQIA youth, Part 2: recognition and management of the unique dermatologic needs of SGM adolescents. Pediatr Dermatol. 2019;36(5):587–593. doi:10.1111/pde.13898
41. Leibowitz S, de Vries ALC. Gender dysphoria in adolescence. Int Rev Psychiatry. 2016;28(1):21–35. doi:10.3109/09540261.2015.1124844
42. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: an Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869–3903. doi:10.1210/jc.2017-01658
43. Giordano S, Holm S. Is puberty delaying treatment ‘experimental treatment’? Int J Transgend Health. 2020;21(2):113–121. doi:10.1080/26895269.2020.1747768
44. Delemarre-van de Waal HA, Cohen-Kettenis PT. Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. Eur J Endocrinology Eur J Endocrinol. 2006;155(suppl_1):S131–S137. doi:10.1530/eje.1.02231
45. Brik T, Vrouenraets L, de Vries MC, Hannema SE. Trajectories of Adolescents Treated with Gonadotropin-Releasing Hormone Analogues for Gender Dysphoria. Arch Sex Behav. 2020;49(7):2611–2618. doi:10.1007/s10508-020-01660-8
46. World Professional Association for Transgender Health. Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People [7th Version]; 2012.
47. Pediatric Endocrine Society. Pediatric Endocrine Society Statement Against Public Discourse That Risks the Well-Being of Transgender and Gender Diverse Youth and Their Families; 2019.
48. de Vries AL, Steensma TD, Doreleijers TA, Cohen-Kettenis PT. Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. J Sex Med. 2011;8(8):2276–2283. doi:10.1111/j.1743-6109.2010.01943.x
49. Tordoff DM, Wanta JW, Collin A, Stepney C, Inwards-Breland DJ, Ahrens K. Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care. JAMA Network Open. 2022;5(2):e220978. doi:10.1001/jamanetworkopen.2022.0978
50. Turban JL, King D, Carswell JM, Keuroghlian AS. Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation. Pediatrics. 2020;145(2):e20191725. doi:10.1542/peds.2019-1725
51. Ragmanauskaite L, Kahn B, Ly B, Yeung H. Acne and the Lesbian, Gay, Bisexual, or Transgender Teenager. Dermatol Clin. 2020;38(2):219–226. doi:10.1016/j.det.2019.10.006
52. Faloia E, Filipponi S, Mancini V, Morosini P, De Pirro R. Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism. J Endocrinol Invest. 1993;16(9):675–677. doi:10.1007/BF03348907
53. Barros B, Thiboutot D. Hormonal therapies for acne. Clin Dermatol. 2017;35(2):168–172.
54. Jensen RK, Jensen JK, Simons LK, Chen D, Rosoklija I, Finlayson CA. Effect of Concurrent Gonadotropin-Releasing Hormone Agonist Treatment on Dose and Side Effects of Gender-Affirming Hormone Therapy in Adolescent Transgender Patients. Transgender Health. 2019;4(1):300–303.
55. Rew L, Young CC, Monge M, Bogucka R. Review: puberty blockers for transgender and gender diverse youth—a critical review of the literature. Child Adolesc Ment Health. 2021;26(1):3–14. doi:10.1111/camh.12437
56. Lucky AW. Hormonal correlates of acne and hirsutism. Am J Med. 1995;98(1a):89s–94s. doi:10.1016/S0002-9343(99)80064-3
57. Tack LJ, Craen M, Dhondt K, Vanden Bossche H, Laridaen J, Cools M. Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis. Biol Sex Differ. 2016;7:14. doi:10.1186/s13293-016-0067-9
58. Stoffers IE, de Vries MC, Hannema SE. Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender dysphoria. J Sex Med. 2019;16(9):1459–1468. doi:10.1016/j.jsxm.2019.06.014
59. Thoreson N, Park JA, Grasso C, et al. Incidence and Factors Associated With Acne Among Transgender Patients Receiving Masculinizing Hormone Therapy. JAMA Dermatol. 2021;157(3):290–295. doi:10.1001/jamadermatol.2020.5347
60. Yeung H, Ragmanauskaite L, Zhang Q, et al. Prevalence of moderate to severe acne in transgender adults: a cross-sectional survey. J Am Acad Dermatol. 2020;83(5):1450–1452. doi:10.1016/j.jaad.2020.02.053
61. Swink SM, Castelo-Soccio L. Dermatologic considerations for transgender and gender diverse youth. Pediatr Dermatol. 2021;38(Suppl 2):58–64. doi:10.1111/pde.14685
62. Endly DC, Miller RA. Oily Skin: a review of Treatment Options. J Clin Aesthet Dermatol. 2017;10(8):49–55.
63. Xu JY, O’Connell MA, Notini L, Cheung AS, Zwickl S, Pang KC. Selective Estrogen Receptor Modulators: a Potential Option For Non-Binary Gender-Affirming Hormonal Care? Front Endocrinol (Lausanne). 2021;12:701364. doi:10.3389/fendo.2021.701364
64. Notini L, Earp BD, Gillam L, et al. Forever young? The ethics of ongoing puberty suppression for non-binary adults. J Med Ethics. 2020;46(11):743. doi:10.1136/medethics-2019-106012
65. Natsuaki M, Yates T. Adolescent Acne and Disparities in Mental Health. Child Dev Perspect. 2021;2:15.
66. Aktan S, Ozmen E, Sanli B. Anxiety, depression, and nature of acne vulgaris in adolescents. Int J Dermatol. 2000;39(5):354–357. doi:10.1046/j.1365-4362.2000.00907.x
67. Kubota Y, Shirahige Y, Nakai K, Katsuura J, Moriue T, Yoneda K. Community-based epidemiological study of psychosocial effects of acne in Japanese adolescents. J Dermatol. 2010;37(7):617–622. doi:10.1111/j.1346-8138.2010.00855.x
68. Jones-Caballero M, Chren MM, Soler B, Pedrosa E, Peñas PF. Quality of life in mild to moderate acne: relationship to clinical severity and factors influencing change with treatment. J Eur Acad Dermatol Venereol. 2007;21(2):219–226. doi:10.1111/j.1468-3083.2006.01907.x
69. Halvorsen JA, Stern RS, Dalgard F, Thoresen M, Bjertness E, Lien L. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol. 2011;131(2):363–370. doi:10.1038/jid.2010.264
70. Davern J, O’Donnell AT. Stigma predicts health-related quality of life impairment, psychological distress, and somatic symptoms in acne sufferers. PLoS One. 2018;13(9):e0205009. doi:10.1371/journal.pone.0205009
71. Xu S, Zhu Y, Hu H, et al. The analysis of acne increasing suicide risk. Medicine. 2021;100(24):e26035. doi:10.1097/MD.0000000000026035
72. Ip A, Muller I, Geraghty AWA, Platt D, Little P, Santer M. Views and experiences of people with acne vulgaris and healthcare professionals about treatments: systematic review and thematic synthesis of qualitative research. BMJ Open. 2021;11(2):e041794. doi:10.1136/bmjopen-2020-041794
73. Reisner SL, Vetters R, Leclerc M, et al. Mental health of transgender youth in care at an adolescent urban community health center: a matched retrospective cohort study. J Adolesc Health. 2015;56(3):274–279. doi:10.1016/j.jadohealth.2014.10.264
74. Veale JF, Watson RJ, Peter T, Saewyc EM. Mental Health Disparities Among Canadian Transgender Youth. J Adolesc Health. 2017;60(1):44–49. doi:10.1016/j.jadohealth.2016.09.014
75. Becerra-Culqui TA, Liu Y, Nash R, et al. Mental Health of Transgender and Gender Nonconforming Youth Compared With Their Peers. Pediatrics. 2018;141(5). doi:10.1542/peds.2017-3845.
76. Di Giacomo E, Krausz M, Colmegna F, Aspesi F, Clerici M. Estimating the Risk of Attempted Suicide Among Sexual Minority Youths: a Systematic Review and Meta-analysis. JAMA Pediatr. 2018;172(12):1145–1152. doi:10.1001/jamapediatrics.2018.2731
77. Liszewski W, Peebles JK, Yeung H, Arron S. Persons of Nonbinary Gender – Awareness, Visibility, and Health Disparities. N Engl J Med. 2018;379(25):2391–2393. doi:10.1056/NEJMp1812005
78. Price-Feeney M, Green AE, Dorison S. Understanding the Mental Health of Transgender and Nonbinary Youth. J Adolesc Health. 2020;66(6):684–690. doi:10.1016/j.jadohealth.2019.11.314
79. Olson KR, Durwood L, DeMeules M, McLaughlin KA. Mental Health of Transgender Children Who Are Supported in Their Identities. Pediatrics. 2016;137(3):e20153223. doi:10.1542/peds.2015-3223
80. Taliaferro LA, McMorris BJ, Rider GN, Eisenberg ME. Risk and Protective Factors for Self-Harm in a Population-Based Sample of Transgender Youth. Arch Suicide Res. 2019;23(2):203–221. doi:10.1080/13811118.2018.1430639
81. Allen LR, Watson LB, Egan AM, Moser CN. Well-being and suicidality among transgender youth after gender-affirming hormones. Clin Practice Pediatric Psychol. 2019;7(3):302. doi:10.1037/cpp0000288
82. Green AE, DeChants JP, Price MN, Davis CK. Association of Gender-Affirming Hormone Therapy With Depression, Thoughts of Suicide, and Attempted Suicide Among Transgender and Nonbinary Youth. J Adolesc Health. 2022;70(4):643–649. doi:10.1016/j.jadohealth.2021.10.036
83. Braun H, Zhang Q, Getahun D, et al. Moderate-to-Severe Acne and Mental Health Symptoms in Transmasculine Persons Who Have Received Testosterone. JAMA Dermatol. 2021;157(3):344–346. doi:10.1001/jamadermatol.2020.5353
84. Covelli I, Ahrens K, Onchiri FM, Inwards-Breland D, Boos MD. Influence of gender and sexual identity on adolescent skin health. Pediatr Dermatol. 2021;38(Suppl 2):65–72. doi:10.1111/pde.14686
85. Cruz TM. Assessing access to care for transgender and gender nonconforming people: a consideration of diversity in combating discrimination. Soc Sci Med. 2014;110:65–73. doi:10.1016/j.socscimed.2014.03.032
86. Riggs DW, Coleman K, Due C. Healthcare experiences of gender diverse Australians: a mixed-methods, self-report survey. BMC Public Health. 2014;14:230. doi:10.1186/1471-2458-14-230
87. Stanton MC, Ali S, Chaudhuri S. Individual, social and community-level predictors of wellbeing in a US sample of transgender and gender non-conforming individuals. Cult Health Sex. 2017;19(1):32–49. doi:10.1080/13691058.2016.1189596
88. Krempasky C, Harris M, Abern L, Grimstad F. Contraception across the transmasculine spectrum. Am J Obstet Gynecol. 2020;222(2):134–143. doi:10.1016/j.ajog.2019.07.043
89. Light AD, Obedin-Maliver J, Sevelius JM, Kerns JL. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014;124(6):1120–1127. doi:10.1097/AOG.0000000000000540
90. Yeung H, Chen SC, Katz KA, Stoff BK. Prescribing isotretinoin in the United States for transgender individuals: ethical considerations. J Am Acad Dermatol. 2016;75(3):648–651. doi:10.1016/j.jaad.2016.03.042
91. Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020;156(6):621–630. doi:10.1001/jamadermatol.2020.0465
92. Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol. 2006;107(5):1120–1138. doi:10.1097/01.AOG.0000216197.26783.b5
93. Grandhi R, Alikhan A. Spironolactone for the Treatment of Acne: a 4-Year Retrospective Study. Dermatology. 2017;233(2–3):141–144. doi:10.1159/000471799
94. Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral Spironolactone for Acne Vulgaris in Adult Females: a Hybrid Systematic Review. Am J Clin Dermatol. 2017;18(2):169–191. doi:10.1007/s40257-016-0245-x
95. Angus L, Leemaqz S, Ooi O, et al. Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy. Endocr Connect. 2019;8(7):935–940. doi:10.1530/EC-19-0272
96. Oge LK, Broussard A, Marshall MD. Acne Vulgaris: diagnosis and Treatment. Am Fam Physician. 2019;100(8):475–484.
97. Fox L, Csongradi C, Aucamp M, du Plessis J, Gerber M. Treatment Modalities for Acne. Molecules. 2016;21(8):1063. doi:10.3390/molecules21081063
98. Carswell JM, Roberts SA. Induction and Maintenance of Amenorrhea in Transmasculine and Nonbinary Adolescents. Transgend Health. 2017;2(1):195–201. doi:10.1089/trgh.2017.0021
99. Administration UFaD. iPLEDGE Risk Evaluation and Mitigation Strategy (REMS). Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems.
100. iPLEDGE. Prescriber isotretinoin educational kit. Available from: https://www.dermla.com/wp-content/uploads/2021/09/Prescriber-Isotretinoin-Educational-Kit-1.pdf.
101. Yeung H, Luk KM, Chen SC, Ginsberg BA, Katz KA. Dermatologic care for lesbian, gay, bisexual, and transgender persons: terminology, demographics, health disparities, and approaches to care. J Am Acad Dermatol. 2019;80(3):581–589. doi:10.1016/j.jaad.2018.02.042
102. Jarrett BA, Corbet AL, Gardner IH, Weinand JD, Peitzmeier SM. Chest Binding and Care Seeking Among Transmasculine Adults: a Cross-Sectional Study. Transgender Health. 2018;3(1):170–178. doi:10.1089/trgh.2018.0017
103. Peitzmeier SM, Silberholz J, Gardner IH, Weinand J, Acevedo K. Time to First Onset of Chest Binding-Related Symptoms in Transgender Youth. Pediatrics. 2021;147(3). doi:10.1542/peds.2020-0728
104. Julian JM, Salvetti B, Held JI, Murray PM, Lara-Rojas L, Olson-Kennedy J. The Impact of Chest Binding in Transgender and Gender Diverse Youth and Young Adults. J Adolescent Health. 2021;68(6):1129–1134. doi:10.1016/j.jadohealth.2020.09.029
105. Peitzmeier S, Gardner I, Weinand J, Corbet A, Acevedo K. Health impact of chest binding among transgender adults: a community-engaged, cross-sectional study. Cult Health Sex. 2017;19(1):64–75. doi:10.1080/13691058.2016.1191675
106. Peitzmeier SM, Gardner IH, Weinand J, Corbet A, Acevedo K. Chest binding in context: stigma, fear, and lack of information drive negative outcomes. Cult Health Sex. 2022;24(2):284–287. doi:10.1080/13691058.2021.1970814
107. Wilson SC, Morrison SD, Anzai L, et al. Masculinizing Top Surgery: a Systematic Review of Techniques and Outcomes. Ann Plast Surg. 2018;80(6):679–683. doi:10.1097/SAP.0000000000001354
108. Perez-Alvarez IM, Zolper EG, Schwitzer J, Fan KL, Del Corral GA. Incidence of Complications in Chest Wall Masculinization for the Obese Female-to-Male Transgender Population: a Case Series. World J Plast Surg. 2021;10(2):14–24. doi:10.52547/wjps.10.2.14
109. Etemad SA, Furuyama WM, Winocour JS. Double Incision Mastectomy with Free Nipple Graft for Masculinizing Chest Wall Surgery. Plast Reconstr Surg Glob Open. 2020;8(11):e3184. doi:10.1097/GOX.0000000000003184
110. Monstrey S, Selvaggi G, Ceulemans P, et al. Chest-Wall Contouring Surgery in Female-to-Male Transsexuals: a New Algorithm. Plast Reconstr Surg. 2008;121(3):849–859. doi:10.1097/01.prs.0000299921.15447.b2
111. Kang S-Y, Um J-Y, Chung B-Y, Kim J-C, Park C-W, Kim H-O. Differential Diagnosis and Treatment of Itching in Children and Adolescents. Biomedicines. 2021;9(8):919. doi:10.3390/biomedicines9080919
112. Tognetti L, Martinelli C, Berti S, et al. Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment: a collaboration between dermatologists and infectivologists. J Eur Acad Dermatol Venereol. 2012;26(8):931–941. doi:10.1111/j.1468-3083.2011.04416.x
113. Lee A, Simpson P, Haire B. The binding practices of transgender and gender-diverse adults in Sydney, Australia. Cult Health Sex. 2019;21(9):969–984. doi:10.1080/13691058.2018.1529335
114. Tollinche LE, Van Rooyen C, Afonso A, Fischer GW, Yeoh CB. Considerations for Transgender Patients Perioperatively. Anesthesiol Clin. 2020;38(2):311–326. doi:10.1016/j.anclin.2020.01.009
115. Poteat T, Malik M, Cooney E. 2148 Understanding the health effects of binding and tucking for gender affirmation. J Clin Translational Sci. 2018;2(S1):76. doi:10.1017/cts.2018.268
116. Malik M, Cooney EE, Brevelle J-M, Poteat T. Tucking Practices and Attributed Health Effects in Transfeminine Individuals. Transgender Health. 2022. doi:10.1089/trgh.2022.0064
117. Swamiappan M. Anogenital Pruritus – An Overview. J Clin Diagn Res. 2016;10(4):We01–03.
118. Williamson C. Providing Care to Transgender Persons: a Clinical Approach to Primary Care, Hormones, and HIV Management. J Assoc Nurses AIDS Care. 2010;21(3):221–229. doi:10.1016/j.jana.2010.02.004
119. Bared A, Epstein JS. Hair Transplantation Techniques for the Transgender Patient. Facial Plast Surg Clin North Am. 2019;27(2):227–232. doi:10.1016/j.fsc.2018.12.005
120. Pang KC, Nguyen TP, Upreti R. Case Report: successful Use of Minoxidil to Promote Facial Hair Growth in an Adolescent Transgender Male. Front Endocrinol (Lausanne). 2021;12:725269. doi:10.3389/fendo.2021.725269
121. Wierckx K, Van de Peer F, Verhaeghe E, et al. Short- and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med. 2014;11(1):222–229.
122. Motosko CC, Zakhem GA, Pomeranz MK, et al. Effect of testosterone on chests and abdomens of transgender men. J Am Acad Dermatol. 2019;81(2):634–636. doi:10.1016/j.jaad.2019.01.030
123. Irwig MS. Is there a role for 5α-reductase inhibitors in transgender individuals? Andrology. 2021;9(6):1729–1731.
124. Capitán L, Simon D, Meyer T, et al. Facial Feminization Surgery: simultaneous Hair Transplant during Forehead Reconstruction. Plast Reconstr Surg. 2017;139(3):573–584. doi:10.1097/PRS.0000000000003149
125. Vilenchik V, Thomas K, Baker L, Hitchens E, Keith D. Laser therapy is a safe and effective treatment for unwanted hair in adults undergoing male to female sex reassignment. Clin Exp Dermatol. 2021;46(3):541–543. doi:10.1111/ced.14466
126. Sabra JJ, Fang CX, Kundu RV, Knowledge-Based A. Assessment of Dermatological Care for Transgender Women. Transgend Health. 2018;3(1):71–73. doi:10.1089/trgh.2018.0001
127. Gao Y, Maurer T, Mirmirani P. Understanding and Addressing Hair Disorders in Transgender Individuals. Am J Clin Dermatol. 2018;19(4):517–527. doi:10.1007/s40257-018-0343-z
128. Bradford NJ, Rider GN, Spencer KG. Hair removal and psychological well-being in transfeminine adults: associations with gender dysphoria and gender euphoria. J Dermatolog Treat. 2021;32(6):635–642. doi:10.1080/09546634.2019.1687823
129. Harris K, Ferguson J, Hills S. A comparative study of hair removal at an NHS hospital: luminette intense pulsed light versus electrolysis. J Dermatolog Treat. 2014;25(2):169–173. doi:10.3109/09546634.2012.715239
130. Görgü M, Aslan G, Aköz T, Erdoğan B. Comparison of alexandrite laser and electrolysis for hair removal. Dermatol Surg. 2000;26(1):37–41. doi:10.1046/j.1524-4725.2000.99104.x
131. Testa RJ, Rider GN, Haug NA, Balsam KF. Gender confirming medical interventions and eating disorder symptoms among transgender individuals. Health Psychol. 2017;36(10):927–936. doi:10.1037/hea0000497
132. Mehringer JE, Harrison JB, Quain KM, Shea JA, Hawkins LA, Dowshen NL. Experience of Chest Dysphoria and Masculinizing Chest Surgery in Transmasculine Youth. Pediatrics. 2021;147(3). doi:10.1542/peds.2020-013300
133. Kamali A, Sigurjónsson H, Gran I, et al. Improved surgical outcome with double incision and free nipple graft in gender confirmation mastectomy. Plast Reconstr Surg Glob Open. 2021;9(7):e3628. doi:10.1097/GOX.0000000000003628
134. Ammari T, Sluiter EC, Gast K, Kuzon WM. Female-to-Male Gender-Affirming Chest Reconstruction Surgery. Aesthetic Surgery J. 2019;39(2):150–163. doi:10.1093/asj/sjy098
135. de Giorgi V, Sestini S, Mannone F, et al. The use of silicone gel in the treatment of fresh surgical scars: a randomized study. Clin Exp Dermatol. 2009;34(6):688–693. doi:10.1111/j.1365-2230.2008.03096.x
136. Garg S, Dahiya N, Gupta S. Surgical scar revision: an overview. J Cutan Aesthet Surg. 2014;7(1):3–13. doi:10.4103/0974-2077.129959
137. Aasi SZ. Z-plasty made simple. Dermatol Res Pract. 2010;2010:982623. doi:10.1155/2010/982623
138. Ragmanauskaite L, Kim J, Zhang Q, et al. Self-reported tattoo prevalence and motivations in transgender adults: a cross-sectional survey. Dermatol Online J. 2020;26(12). doi:10.5070/D32612051353.
139. Drost BH, van de Langenberg R, Manusama OR, et al. Dermatography (Medical Tattooing) for Scars and Skin Grafts in Head and Neck Patients to Improve Appearance and Quality of Life. JAMA Facial Plast Surg. 2017;19(1):16–22. doi:10.1001/jamafacial.2016.1084
140. Naides AI, Schultz JJ, Shulzhenko NO, Keith JD. Chest Masculinization Technique and Outcomes in 72 Double-incision Chest-contouring Procedures with Free Nipple Grafting. Plastic Reconstructive Surgery. 2021;9(3):e3459. doi:10.1097/GOX.0000000000003459
141. Trisliana Perdanasari A, Torresetti M, Grassetti L, et al. Intralesional injection treatment of hypertrophic scars and keloids: a systematic review regarding outcomes. Burns Trauma. 2015;3:14. doi:10.1186/s41038-015-0015-7
142. Mercer NS. Silicone gel in the treatment of keloid scars. Br J Plast Surg. 1989;42(1):83–87. doi:10.1016/S0007-1226(89)90119-7
143. Committee Opinion No. 685: care for Transgender Adolescents. Obstet Gynecol. 2017;129(1):e11–e16. doi:10.1097/AOG.0000000000001861
144. Bretschneider CE, Sheyn D, Pollard R, Ferrando CA. Complication Rates and Outcomes After Hysterectomy in Transgender Men. Obstet Gynecol. 2018;132(5):1265–1273. doi:10.1097/AOG.0000000000002936
145. McCarus SD. Scar assessment for patients undergoing minimal invasive hysterectomy. Surg Technol Int. 2014;25:150–156.
146. Kailas M, Lu HMS, Rothman EF, Safer JD. Prevalence and Types of Gender-Affirming Surgery Among A Sample of Transgender Endocrinology Patients Prior to State Expansion of Insurance Coverage. Endocrine Practice. 2017;23(7):780–786. doi:10.4158/EP161727.OR
147. de Blok CJM, Staphorsius AS, Wiepjes CM, Smit JM, Nanayakkara PWB, den Heijer M. Frequency, Determinants, and Satisfaction of Breast Augmentation in Trans Women Receiving Hormone Treatment. J Sex Med. 2020;17(2):342–348. doi:10.1016/j.jsxm.2019.10.021
148. Gaither TW, Awad MA, Osterberg EC, et al. Postoperative Complications following Primary Penile Inversion Vaginoplasty among 330 Male-to-Female Transgender Patients. J Urol. 2018;199(3):760–765. doi:10.1016/j.juro.2017.10.013
149. van der Sluis WB, Smit JM, Pigot GLS, et al. Double flap phalloplasty in transgender men: surgical technique and outcome of pedicled anterolateral thigh flap phalloplasty combined with radial forearm free flap urethral reconstruction. Microsurgery. 2017;37(8):917–923. doi:10.1002/micr.30190
150. Bordas N, Stojanovic B, Bizic M, Szanto A, Djordjevic ML. Metoidioplasty: surgical Options and Outcomes in 813 Cases. Front Endocrinol (Lausanne). 2021;12:760284. doi:10.3389/fendo.2021.760284
151. Kcomt L, Gorey KM, Barrett BJ, McCabe SE. Healthcare avoidance due to anticipated discrimination among transgender people: a call to create trans-affirmative environments. SSM Popul Health. 2020;11:100608. doi:10.1016/j.ssmph.2020.100608
152. Safer JD, Coleman E, Feldman J, et al. Barriers to healthcare for transgender individuals. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):168–171. doi:10.1097/MED.0000000000000227
153. Boos MD, Yeung H, Inwards-Breland D. Dermatologic care of sexual and gender minority/LGBTQIA youth, Part I: an update for the dermatologist on providing inclusive care. Pediatr Dermatol. 2019;36(5):581–586. doi:10.1111/pde.13896
154. Haider A, Adler RR, Schneider E, et al. Assessment of Patient-Centered Approaches to Collect Sexual Orientation and Gender Identity Information in the Emergency Department: the EQUALITY Study. JAMA Netw Open. 2018;1(8):e186506. doi:10.1001/jamanetworkopen.2018.6506
155. Hashemi L, Weinreb J, Weimer AK, Weiss RL. Transgender care in the primary care setting: a review of guidelines and literature. Fed Pract. 2018;35(7):30–37.
156. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg. 2005;24(2):92–102. doi:10.1016/j.sder.2005.04.003
157. Huang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;76(6):1068–1076.e1069. doi:10.1016/j.jaad.2016.12.028
158. Johnson B, Leibowitz S, Chavez A, Herbert SE. Risk Versus resiliency: addressing depression in lesbian, gay, bisexual, and transgender youth. Child Adolesc Psychiatr Clin N Am. 2019;28(3):509–521. doi:10.1016/j.chc.2019.02.016